Catastrophic antiphospholipid syndrome in an immune thrombocytopenia patient treated with avatrombopag

被引：5

作者：

Van de Vondel, Saartje ^{[1
]}

Vandenbriele, Christophe ^{[2
]}

Gheysens, Gerald ^{[3
]}

Verhamme, Peter ^{[2
]}

Janssens, Ann ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Hematol, Leuven, Belgium

[2] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Cardiovasc Sci, Leuven, Belgium

[3] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Radiol, Leuven, Belgium

来源：

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS | 2023年 / 7卷 / 03期

关键词：

ANTIBODIES; MANAGEMENT; DIAGNOSIS; PURPURA;

D O I：

10.1016/j.rpth.2023.100125

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Avatrombopag is an orally administered second-generation thrombopoietin receptor agonist (TPO-RA) approved for the treatment of chronic immune thrombocytopenia (ITP). However, increased thrombogenicity in patients with ITP after initiation of TPO-RA treatment has been reported.Key Clinical Question: We report a case of a patient with ITP who developed a catastrophic antiphospholipid antibody syndrome (CAPS), following treatment with avatrombopag.Clinical Approach: A 20-year-old known chronic patient with ITP presented at the emergency department with a 2-week history of headache, nausea, and abdominal pain, 3 weeks after initiating avatrombopag. In-hospital diagnostic work-up revealed multiple microvascular thrombotic events, including myocardial, cerebrovascular, and pulmonary infarctions. Laboratory test results showed a triple-positive antiphospholipid antibodies serology. Conclusion: The diagnosis of probable avatrombopag-associated CAPS was made.

引用

页数：5

共 50 条

[31] Catastrophic antiphospholipid syndrome
Cervera, Ricard
Asherson, Ronald A.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2006, 35 (1-2) : 181 - 186
[32] Catastrophic antiphospholipid syndrome
Furmanczyk, Agnieszka
Komuda-Leszek, Ewa
Gadomska, Wioletta
Windyga, Jerzy
Durlik, Magdalena
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2009, 119 (06): : 427 - 430
[33] The catastrophic antiphospholipid syndrome
LeLoet, X
Vittecoq, O
JouenBeades, F
Tron, F
PRESSE MEDICALE, 1997, 26 (03): : 131 - 134
[34] Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab
Ruffatti, Amelia
Tarzia, Vincenzo
Fedrigo, Marry
Calligaro, Antonia
Favaro, Maria
Macor, Paolo
Tison, Tiziana
Cucchini, Umberto
Cosmi, Erich
Tedesco, Francesco
Angelini, Annalisa
Gerosa, Gino
AUTOIMMUNITY REVIEWS, 2019, 18 (05) : 561 - 563
[35] Catastrophic antiphospholipid syndrome
Arbabi, Esmaeil M.
Carrim, Zia I.
Doherty, Mark D.
Vize, Colin J.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2013, 41 (06): : 609 - 611
[36] Catastrophic antiphospholipid syndrome
Asherson, RA
Cervera, R
CURRENT OPINION IN HEMATOLOGY, 2000, 7 (05) : 325 - 329
[37] Catastrophic antiphospholipid syndrome
Costedoat-Chalumeau, N.
Chastre, J.
Piette, J-C
REVUE DE MEDECINE INTERNE, 2012, 33 : S21 - S24
[38] 'Catastrophic' antiphospholipid syndrome
Maddison, PJ
Thorpe, C
Seale, JRC
Ahmed, W
Whiteley, GS
LUPUS, 2000, 9 (07) : 484 - 488
[39] THE CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME
ASHERSON, RA
JOURNAL OF RHEUMATOLOGY, 1992, 19 (04) : 508 - 512
[40] Catastrophic antiphospholipid syndrome
Joan T Merrill
Ronald A Asherson
Nature Clinical Practice Rheumatology, 2006, 2 : 81 - 89

← 1 2 3 4 5 →